A healthy bone marrow responds to the body’s chemical signals that essentially communicate the need to boost blood cell production. Most of the hematopoietic stem cells live and work in the bone marrow. Hematopoietic stem cells give rise to all types of blood cells such as White Blood Cells, Red Blood Cells, and platelets. Without a healthy bone marrow, blood cell production suffers and new ones cannot be made. One of the side effects of chemotherapy in cancer patients is damage to the bone marrow, which hinders the ability to develop new blood cells, especially WBC. Hematologic malignancies are also responsible for an unhealthy bone marrow. Pharmaceutical companies have developed drugs known as growth factors or colony-stimulating factors that can be used to boost the production of blood cells.

There is a rise in the use of therapies such as chemotherapy and radiotherapy, which lead to damage to the bone marrow. This is boosting demand for bone marrow stimulator drugs in the market. According to the World Cancer Research Fund International, there were an estimated 18 million cancer cases around the world in 2018. Moreover, the Global Burden of Disease study data stated that the incidence of leukemia increased by 26% from 2006 to 2016.

The global bone marrow stimulator drugs market can be segmented based on drugs class, distribution channel, and region. Based on drug class, the global bone marrow stimulator drugs market can be classified into filgrastim, lenograstim, and others. The filgrastim segment dominated the bone marrow stimulator drugs market in 2017.  This is because filgrastim is a non-glycosylated stimulating factor that effectively binds with the bone marrow and stimulates it to develop WBCs in large numbers.  In terms of distribution channel, the bone marrow stimulator drugs market can be categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment dominates the market. This is because bone marrow stimulator drugs can be given to patients under observation in order to check the effect of the drugs on WBC count. Therefore, a large number of patients prefer to buy the drugs through hospital pharmacies.

In terms of region, the global bone marrow stimulator drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017. The region is projected to account for a significant share of the global bone marrow stimulator drugs market during the forecast period, owing to a high incidence of cancer and wide availability of all the types of bone marrow stimulator drugs in North America. In 2018, Pfizer launched the bio similar drug of filgrastim called NIVESTYM in the U.S. market. High awareness about the effect of cancer treatment and rise in the incidence of blood disorders among the European population are expected to drive the bone marrow stimulator drugs market in Europe.

Major players operating in the global bone marrow stimulator drugs market include Amgen Inc. Teva Pharmaceutical, Novartis AG, Pfizer Inc. F. Hoffmann-La Roche AG, and Lupin Pharmaceuticals, Inc..

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Bone Marrow Stimulator Drugs Market

Pre Book